Stock listing
EUROTLX:4BIIB Biogen Inc. Azioni
Italian listing (EUROTLX) of Biogen Inc. · home listing NASDAQ:BIIB
Follow Biogen Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:BIIB
$240.98 USD -2.12 (-0.9%)
Close on Oct 21, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:BIIB
- Day range
- $240.15 – $243.32 USDOct 21, 2026
- Volume
- 812,875 sharesOct 21, 2026
- Market cap
- $35.61B USDAt the close on Oct 21, 2026 · price × 147.8M shares outstanding
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:BIIB · Home | $240.98 USD | -2.12 (-0.9%) | 812,875 | $242.02 | $243.32 | $240.15 | $243.10 | Close on Oct 21, 2026 |
| LSE:0R1B | $241.38 USD | -1.68 (-0.7%) | 194 | $246.64 | $247.04 | $238.01 | $243.06 | Close on Oct 21, 2026 |
| Frankfurt:IDP | €214.10 EUR | -1.00 (-0.5%) | 350 | €216.15 | €216.40 | €214.10 | €215.10 | Close on Oct 21, 2026 |
| B3:BIIB34 | 193.80 BRL | — | 27 | 193.80 | 193.80 | 193.80 | — | Close on Oct 14, 2026 |
| Hamburg:IDP | €215.40 EUR | -0.65 (-0.3%) | — | €216.15 | €216.25 | €215.40 | €216.05 | Close on Oct 21, 2026 |
| Munich:IDP | €216.95 EUR | +8.65 (+4.2%) | — | €216.95 | €216.95 | €216.95 | €208.30 | Close on Oct 21, 2026 |
| Dusseldorf:IDP | €213.90 EUR | -1.85 (-0.9%) | — | €216.00 | €216.00 | €213.90 | €215.75 | Close on Oct 21, 2026 |
Daily closes
Last 3 months, Jul 21, 2026 – Oct 21, 2026 · NASDAQ:BIIB · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $240.98 | -2.12 | -0.9% | $242.02 | $243.32 | $240.15 | 812,875 | |
| $243.10 | +9.62 | +4.1% | $236.79 | $244.65 | $236.24 | 1,491,975 | |
| $233.48 | +0.83 | +0.4% | $232.00 | $236.00 | $231.04 | 949,473 | |
| $232.65 | -2.70 | -1.1% | $235.77 | $236.74 | $232.46 | 1,462,552 | |
| $235.35 | +2.52 | +1.1% | $236.48 | $240.99 | $235.22 | 1,572,408 | |
| $232.83 | +3.93 | +1.7% | $228.99 | $234.20 | $228.00 | 1,947,100 | |
| $228.90 | -0.51 | -0.2% | $230.34 | $231.04 | $226.71 | 1,049,113 | |
| $229.41 | +3.70 | +1.6% | $233.98 | $238.24 | $229.00 | 1,461,700 | |
| $225.71 | +7.28 | +3.3% | $220.62 | $227.20 | $219.23 | 815,000 | |
| $218.43 | -3.72 | -1.7% | $220.15 | $223.09 | $215.73 | 1,339,000 | |
| $222.15 | -0.74 | -0.3% | $222.93 | $228.00 | $221.40 | 1,298,100 | |
| $222.89 | -0.70 | -0.3% | $224.53 | $225.97 | $218.00 | 1,008,100 | |
| $223.59 | +3.71 | +1.7% | $219.90 | $223.85 | $218.22 | 951,300 | |
| $219.88 | -2.94 | -1.3% | $222.98 | $224.08 | $219.81 | 779,900 | |
| $222.82 | -3.06 | -1.4% | $225.50 | $228.31 | $222.50 | 1,755,300 | |
| $225.88 | -1.19 | -0.5% | $227.23 | $229.36 | $225.51 | 1,553,300 | |
| $227.07 | -1.62 | -0.7% | $227.02 | $229.41 | $224.45 | 1,161,200 | |
| $228.69 | +1.09 | +0.5% | $225.87 | $230.49 | $225.51 | 1,332,300 | |
| $227.60 | +1.24 | +0.5% | $228.27 | $228.92 | $223.76 | 958,000 | |
| $226.36 | -1.17 | -0.5% | $226.80 | $228.72 | $224.31 | 1,034,600 | |
| $227.53 | +2.17 | +1.0% | $226.94 | $229.19 | $222.36 | 1,494,300 | |
| $225.36 | +6.29 | +2.9% | $219.22 | $226.43 | $219.00 | 1,111,700 | |
| $219.07 | +3.57 | +1.7% | $216.14 | $221.92 | $214.59 | 928,500 | |
| $215.50 | -3.55 | -1.6% | $219.05 | $220.17 | $215.26 | 2,634,700 | |
| $219.05 | +3.04 | +1.4% | $217.68 | $219.41 | $215.33 | 836,700 | |
| $216.01 | -0.16 | -0.1% | $216.41 | $218.29 | $214.81 | 606,500 | |
| $216.17 | -1.19 | -0.5% | $216.71 | $216.71 | $213.54 | 756,000 | |
| $217.36 | +0.21 | +0.1% | $221.00 | $222.25 | $215.56 | 629,900 | |
| $217.15 | +1.72 | +0.8% | $216.75 | $219.76 | $214.71 | 1,075,600 | |
| $215.43 | +4.70 | +2.2% | $209.92 | $216.70 | $208.93 | 936,600 | |
| $210.73 | -1.77 | -0.8% | $210.50 | $213.48 | $209.00 | 694,600 | |
| $212.50 | -8.33 | -3.8% | $215.45 | $217.28 | $210.54 | 617,600 | |
| $220.83 | -3.68 | -1.6% | $221.15 | $223.82 | $219.82 | 465,100 | |
| $224.51 | +1.84 | +0.8% | $225.44 | $225.80 | $221.23 | 550,700 | |
| $222.67 | +6.63 | +3.1% | $218.20 | $225.59 | $216.97 | 1,268,200 | |
| $216.04 | -0.61 | -0.3% | $218.11 | $219.30 | $213.60 | 785,500 | |
| $216.65 | -1.85 | -0.8% | $216.47 | $218.89 | $213.58 | 831,000 | |
| $218.50 | -3.00 | -1.4% | $221.17 | $222.00 | $216.78 | 517,400 | |
| $221.50 | +0.43 | +0.2% | $219.39 | $222.11 | $217.53 | 497,300 | |
| $221.07 | +0.30 | +0.1% | $219.34 | $222.00 | $218.69 | 647,200 | |
| $220.77 | +2.65 | +1.2% | $218.93 | $222.85 | $218.00 | 495,400 | |
| $218.12 | +1.34 | +0.6% | $216.40 | $218.50 | $213.96 | 649,800 | |
| $216.78 | +2.43 | +1.1% | $217.76 | $219.12 | $215.00 | 722,300 | |
| $214.35 | -7.21 | -3.3% | $217.98 | $221.29 | $214.16 | 808,600 | |
| $221.56 | +9.01 | +4.2% | $215.33 | $222.15 | $215.08 | 886,800 | |
| $212.55 | +3.40 | +1.6% | $211.00 | $214.07 | $210.01 | 694,000 | |
| $209.15 | -0.68 | -0.3% | $208.36 | $210.49 | $207.62 | 617,100 | |
| $209.83 | -0.82 | -0.4% | $210.01 | $210.79 | $208.22 | 554,400 | |
| $210.65 | +1.78 | +0.9% | $212.98 | $215.61 | $208.79 | 860,100 | |
| $208.87 | +4.98 | +2.4% | $203.52 | $209.22 | $201.00 | 789,000 | |
| $203.89 | -3.24 | -1.6% | $206.63 | $207.57 | $203.53 | 936,800 | |
| $207.13 | -0.81 | -0.4% | $206.70 | $210.02 | $206.29 | 706,400 | |
| $207.94 | +1.66 | +0.8% | $207.38 | $208.31 | $204.16 | 840,500 | |
| $206.28 | -0.35 | -0.2% | $208.75 | $209.03 | $202.03 | 892,600 | |
| $206.63 | -1.82 | -0.9% | $210.60 | $212.18 | $205.80 | 873,700 | |
| $208.45 | +6.63 | +3.3% | $200.96 | $209.74 | $199.93 | 1,205,400 | |
| $201.82 | -1.13 | -0.6% | $203.34 | $203.85 | $199.58 | 940,900 | |
| $202.95 | -4.98 | -2.4% | $207.51 | $208.05 | $202.57 | 1,062,000 | |
| $207.93 | -1.30 | -0.6% | $204.38 | $210.19 | $203.09 | 892,900 | |
| $209.23 | +3.62 | +1.8% | $210.50 | $218.59 | $206.27 | 2,400,100 | |
| $205.61 | +5.47 | +2.7% | $201.01 | $207.72 | $199.40 | 1,831,900 | |
| $200.14 | -2.05 | -1.0% | $202.75 | $204.47 | $199.83 | 762,600 | |
| $202.19 | +1.57 | +0.8% | $202.24 | $203.30 | $200.04 | 596,300 | |
| $200.62 | +2.88 | +1.5% | $197.04 | $203.60 | $196.92 | 1,032,100 | |
| $197.74 | -5.42 | -2.7% | $203.70 | $204.31 | $197.40 | 841,300 | |
| $203.16 | +3.21 | +1.6% | $199.47 | $203.70 | $198.59 | 652,800 |
- Ticker
- EUROTLX:4BIIB
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- EUROTLX
- Currency
- EUR
What changed lately
Latest news release · Oct 19, 2026
Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week
Latest earnings call · Jul 29, 2026
Biogen (NASDAQ:BIIB) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Jul 29, 2026
Q2 2026 Earnings Presentation
Earnings · 34 slides
Calls
Upcoming
Biogen (NASDAQ:BIIB) Q3 2026 Earnings Call
Wed, Oct 28, 2026 · 8:30 AM ET
Register
Replays
Biogen (NASDAQ:BIIB) Q2 2026 Earnings Call
Wed, Jul 29, 2026 · 8:30 AM ET
Watch TranscriptBiogen (NASDAQ:BIIB) Q1 2026 Earnings Call
Wed, Apr 29, 2026 · 8:00 AM ET
Watch TranscriptBiogen (NASDAQ:BIIB) Q4 2025 Earnings Call
Fri, Feb 06, 2026 · 8:30 AM ET
Watch Transcript
Latest news
Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week
Oct 19, 2026
Closed $233.48 (+0.4%) on Oct 19, 2026
Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
Oct 2, 2026
Closed $219.88 (-1.3%) on Oct 2, 2026
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
Sep 17, 2026
Closed $215.50 (-1.6%) on Sep 18, 2026
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease
Sep 16, 2026
Closed $216.01 (-0.1%) on Sep 16, 2026
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China
Sep 3, 2026
Closed $224.51 (+0.8%) on Sep 3, 2026
Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease
Aug 31, 2026
Closed $216.04 (-0.3%) on Sep 1, 2026
Veeva Vault CRM Selected by Biogen
Aug 25, 2026
Closed $220.77 (+1.2%) on Aug 25, 2026
Issued by another party
LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease
Aug 24, 2026
Closed $218.12 (+0.6%) on Aug 24, 2026
Biogen Completes Acquisition of RayThera Inc.
Aug 6, 2026
Closed $207.94 (+0.8%) on Aug 7, 2026
Biogen Reports Second Quarter 2026 Results
Jul 29, 2026
Closed $209.23 (+1.8%) on Jul 29, 2026
Decks
Q2 2026 Earnings Presentation
Earnings · 34 slides · Jul 29, 2026
AAIC 2026
Conference · 21 slides · Jul 14, 2026
Q1 2026 Earnings Presentation
Earnings · 31 slides · Apr 29, 2026
Merger or Acquisition (March 2026)
Merger or acquisition · 12 slides · Mar 31, 2026
Biogen Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 78 in the last 12 months · 240 in all · newest Oct 19, 2026 · oldest 2021
- Calls
- 26 calls with a replay · 26 with a transcript · latest Jul 29, 2026
- Decks
- 51 decks · latest Jul 29, 2026
Where Biogen Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:BIIB · Home listing | NASDAQ | United States | USD |
| gettex:IDP | gettex | Germany | EUR |
| BCBA:BIIB | BCBA | Argentina | ARS |
| Tradegate:IDP | Tradegate | Germany | EUR |
| LS Exchange:789617 | LS Exchange | Germany | EUR |
| BMV:BIIB | BMV | Mexico | MXN |
| BCBA:BIIBD | BCBA | Argentina | USD |
| Lang & Schwarz:789617 | Lang & Schwarz | Germany | EUR |
| BCS:BIIB | BCS | Chile | USD |
| LSE:0R1B | LSE | United Kingdom | USD |
| Frankfurt:IDP | Frankfurt | Germany | EUR |
| Milan:1BIIB | Milan | Italy | EUR |
| B3:BIIB34 | B3 | Brazil | BRL |
| BOATS:BIIB | BOATS | United States | USD |
| Stuttgart:IDP | Stuttgart | Germany | EUR |
| BIVA:BIIB | BIVA | Mexico | MXN |
| Hamburg:IDP | Hamburg | Germany | EUR |
| SIX Swiss:BIIB.USD | SIX Swiss | Switzerland | USD |
| Munich:IDP | Munich | Germany | EUR |
| VIE:BIIB | Vienna | Austria | EUR |
| Dusseldorf:IDP | Dusseldorf | Germany | EUR |
| Hanover:IDP | Hanover | Germany | EUR |
| SIX Swiss:BIIB | SIX Swiss | Switzerland | CHF |
| BCS:BIIBCL | BCS | Chile | CLP |
| Turquoise:BIIBN | Turquoise | United Kingdom | USD |
| BCBA:BIIBC | BCBA | Argentina | USD |
| EUROTLX:4BIIB · This page | EUROTLX | Italy | EUR |
| BX Swiss:IDP | BX Swiss | Switzerland | CHF |
| BCBA:BIIB.CI | BCBA | Argentina | ARS |
| Xetra:IDP | Xetra | Germany | EUR |
Log in to ask 6ix AI your own questions about Biogen Inc.